Investigating the efficacy and safety of Myrtus nasal spray in controlling the symptoms of patients with mild COVID-19

ABSTRACT

ConditionCOVID-19.
Covid-19;U07.1

InterventionIntervention 1 Intervention group Myrtus nasal spray 1 puff into each nostril every 8 hours, for 14 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2 Control group Routine treatment according to the latest national guideline for the treatment of new corona-virus.

Primary outcome:Clinical symptoms (dry cough). Timepoint Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement Thermometer.

CriteriaInclusion criteria Age equal or more than 18 years;
The patient have written consciously and freely consent to participate in the study;
The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19.
Confirmed diagnosis of COVID-19, with RT-PCR confirmation.
Less than 7 days have passed since the onset of symptoms.

Exclusion criteria History of allergy to this nasal spray ingredients;
The patient is in another clinical trial at the same time;
The patient needs to receive medical care from the inpatient care;
Pregnancy;
Lactation.